Form 10-K
ONCOCYTE CORP filed this Form 10-K on 04/01/2019
Document Outline
Entire Document (3409.3 KB)
Subdocument 1 - 10-K
Page 1 - UNITED STATES
Page 2 - OncoCyte Corporation
Page 3 - PART I
Page 4 - Business
Page 5 - DetermaVu Lung Cancer Diagnostic Test
Page 6 - DetermaVuTM Market Opportunity
Page 7 - Current Standard of Care
Page 8 - N/A
Page 9 - Use of DetermaVu in the Lung Nodule Standard of Care
Page 10 - The Development Pathway and Milestones
Page 11 - Diagnostic Development Stages
Page 12 - Analytical Validation. The fourth stage Analytical Validation is conducted in our CLIA laboratory an
Page 13 - About Our CLIA Diagnostic Laboratory
Page 14 - Licensed Technology from Wistar
Page 15 - Facilities
Page 16 - Market Access Reimbursement
Page 17 - N/A
Page 18 - Patents and Trade Secrets
Page 19 - N/A
Page 20 - Government Regulation
Page 21 - N/A
Page 22 - N/A
Page 23 - Employees
Page 24 - Risk Factors
Page 25 - If our laboratory facilities become damaged or inoperable, or we are required to vacate any facility
Page 26 - The research and development work we are doing is costly, time consuming, and uncertain as to its re
Page 27 - We may become dependent on possible future collaborations to develop and commercialize many of our d
Page 28 - Our business and operations could suffer in the event of system failures.
Page 29 - Risks Related to Our Industry
Page 30 - We will also need to obtain FDA and other regulatory approvals for any IVDs that we may develop, in
Page 31 - If the FDA regulates LDTs such as the ones we are developing, we may be subject to a medical device
Page 32 - Because of certain Medicare billing policies, we may not receive complete reimbursement for tests pr
Page 33 - If we are successful in commercializing DetermaVuTM or other diagnostic tests, we will be obligated
Page 34 - We may not be able to obtain patent protection for our diagnostic test if our pending U.S. patent ap
Page 35 - If we are unable to protect the confidentiality of our trade secrets, the value of our technology co
Page 36 - If we are sued for infringing intellectual property rights of third parties, such litigation could b
Page 37 - Risks Related to Our Relationship with BioTime
Page 38 - Conflicts of interest with BioTime could arise from our ownership of BioTime common shares and BioTi
Page 39 - The implementation of a new FASB accounting standard could increase the risk that our future financi
Page 40 - You may experience dilution of your ownership interests if we issue additional shares of common stoc
Page 41 - PART II
Page 42 - ITEM 7. Management s Discussion and Analysis of Financial Condition and Results of Operations
Page 43 - N/A
Page 44 - N/A
Page 45 - Results of Operations
Page 46 - Income taxes
Page 47 - Liquidity and Capital Resources
Page 48 - Off-Balance Sheet Arrangements
Page 49 - Report of Independent Registered Public Accounting Firm
Page 50 - ONCOCYTE CORPORATION
Page 51 - ONCOCYTE CORPORATION
Page 52 - ONCOCYTE CORPORATION
Page 53 - ONCOCYTE CORPORATION
Page 54 - ONCOCYTE CORPORATION
Page 55 - ONCOCYTE CORPORATION
Page 56 - N/A
Page 57 - N/A
Page 58 - N/A
Page 59 - N/A
Page 60 - N/A
Page 61 - N/A
Page 62 - 3. Selected Balance Sheet Components
Page 63 - 5. Loan Payable to Silicon Valley Bank
Page 64 - 6. Shareholders Equity
Page 65 - N/A
Page 66 - N/A
Page 67 - 7. Stock-Based Compensation
Page 68 - N/A
Page 69 - N/A
Page 70 - 8. Income Taxes
Page 71 - N/A
Page 72 - 9. Commitments and Contingencies
Page 73 - N/A
Page 74 - 10. Subsequent Events
Page 75 - N/A
Page 76 - PART III
Page 77 - PART IV
Page 78 - N/A
Page 79 - N/A
Page 80 - N/A
Page 81 - N/A
Subdocument 2 - EX-10.26 - Material contracts
Page 1 - N/A
Page 2 - Award Documents ), any of Executive s unvested outstanding Company option grants, ( Company Options
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR S
Page 7 - N/A
Page 8 - [Signature Page to the Separation Agreement Follows]
Page 9 - EXECUTIVE
Page 10 - Exhibit A
Page 11 - I acknowledge that neither the Company nor its agents have recommended or influenced my decision to
Page 12 - N/A
Subdocument 3 - EX-23.1 - Consents of experts and counsel
Page 1 - exhibit 23.1
Page 2 - N/A
Subdocument 4 - EX-31 - Certifications required under Section 302 of the Sarbanes-Oxley Act of 2002
Page 1 - Exhibit 31
Page 2 - Exhibit 31
Page 3 - N/A
Subdocument 5 - EX-32 - Certifications required under Section 906 of the Sarbanes-Oxley Act of 2002
Page 1 - Exhibit 32
Page 2 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE FILE (What's this?)
XBRL Item - EX-101.SCH - XBRL SCHEMA FILE (What's this?)
XBRL Item - EX-101.CAL - XBRL CALCULATION FILE (What's this?)
XBRL Item - EX-101.DEF - XBRL DEFINITION FILE (What's this?)
XBRL Item - EX-101.LAB - XBRL LABEL FILE (What's this?)
XBRL Item - EX-101.PRE - XBRL PRESENTATION FILE (What's this?)
XBRL Viewer